Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion

Margarita Polgár, L. Vereczkey, I. Nyáry

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The pharmacokinetics of vinpocetine (ethyl apovincaminate, Cavinton) and its metabolite, apovincaminic acid, was studied in patients with cerebrovascular disorders. Vinpocetine (1 mg/kg) was infused intravenously over 25 min. The elimination half-life of the parent drug in plasma was 4.7±2.13 h. Total clearance of vinpocetine was 0.79±0.1 1 h-1 kg-1. The presence of vinpocetine in cerebrospinal fluid shows that the drug is able to pass through the blood-brain barrier and reach the central nervous system which is a possible site of action. The maximum increase of cerebral blood flow (25%) was measured at 32 min after the start of the infusion.

Original languageEnglish
Pages (from-to)131-139
Number of pages9
JournalJournal of Pharmaceutical and Biomedical Analysis
Volume3
Issue number2
DOIs
Publication statusPublished - 1985

Fingerprint

vinpocetine
Cerebrospinal fluid
Pharmacokinetics
Metabolites
Intravenous Infusions
Cerebrospinal Fluid
Plasmas
Cerebrovascular Circulation
Cerebrovascular Disorders
Neurology
Blood-Brain Barrier
Pharmaceutical Preparations
Half-Life
apovincaminic acid
Blood
Central Nervous System
Parents

Keywords

  • apovincaminic acid
  • cerebral blood flow.
  • cerebrospinal fluid
  • pharmacokinetics in patients
  • Vinpocetine

ASJC Scopus subject areas

  • Analytical Chemistry
  • Pharmaceutical Science

Cite this

@article{abe9f9f67a0a42b8ab779d9403d4ac4d,
title = "Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion",
abstract = "The pharmacokinetics of vinpocetine (ethyl apovincaminate, Cavinton) and its metabolite, apovincaminic acid, was studied in patients with cerebrovascular disorders. Vinpocetine (1 mg/kg) was infused intravenously over 25 min. The elimination half-life of the parent drug in plasma was 4.7±2.13 h. Total clearance of vinpocetine was 0.79±0.1 1 h-1 kg-1. The presence of vinpocetine in cerebrospinal fluid shows that the drug is able to pass through the blood-brain barrier and reach the central nervous system which is a possible site of action. The maximum increase of cerebral blood flow (25{\%}) was measured at 32 min after the start of the infusion.",
keywords = "apovincaminic acid, cerebral blood flow., cerebrospinal fluid, pharmacokinetics in patients, Vinpocetine",
author = "Margarita Polg{\'a}r and L. Vereczkey and I. Ny{\'a}ry",
year = "1985",
doi = "10.1016/0731-7085(85)80016-9",
language = "English",
volume = "3",
pages = "131--139",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion

AU - Polgár, Margarita

AU - Vereczkey, L.

AU - Nyáry, I.

PY - 1985

Y1 - 1985

N2 - The pharmacokinetics of vinpocetine (ethyl apovincaminate, Cavinton) and its metabolite, apovincaminic acid, was studied in patients with cerebrovascular disorders. Vinpocetine (1 mg/kg) was infused intravenously over 25 min. The elimination half-life of the parent drug in plasma was 4.7±2.13 h. Total clearance of vinpocetine was 0.79±0.1 1 h-1 kg-1. The presence of vinpocetine in cerebrospinal fluid shows that the drug is able to pass through the blood-brain barrier and reach the central nervous system which is a possible site of action. The maximum increase of cerebral blood flow (25%) was measured at 32 min after the start of the infusion.

AB - The pharmacokinetics of vinpocetine (ethyl apovincaminate, Cavinton) and its metabolite, apovincaminic acid, was studied in patients with cerebrovascular disorders. Vinpocetine (1 mg/kg) was infused intravenously over 25 min. The elimination half-life of the parent drug in plasma was 4.7±2.13 h. Total clearance of vinpocetine was 0.79±0.1 1 h-1 kg-1. The presence of vinpocetine in cerebrospinal fluid shows that the drug is able to pass through the blood-brain barrier and reach the central nervous system which is a possible site of action. The maximum increase of cerebral blood flow (25%) was measured at 32 min after the start of the infusion.

KW - apovincaminic acid

KW - cerebral blood flow.

KW - cerebrospinal fluid

KW - pharmacokinetics in patients

KW - Vinpocetine

UR - http://www.scopus.com/inward/record.url?scp=0022000519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022000519&partnerID=8YFLogxK

U2 - 10.1016/0731-7085(85)80016-9

DO - 10.1016/0731-7085(85)80016-9

M3 - Article

C2 - 16867695

AN - SCOPUS:0022000519

VL - 3

SP - 131

EP - 139

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

IS - 2

ER -